Genetic and environmental factors in neurodegenerative diseases

Oxidative Stress and Neurodegenerative Disorders

Volumn , Issue , 2007, Pages 89-114

  Coppedè, Fabio ^a   Migliore, Lucia ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882552897     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044452809-4/50144-7     Document Type: Chapter

References (163)

1. RN Rosenberg (2000) The molecular and genetic basis of Alzheimer's disease: the end of the beginning. Neurology 54 2045-2054.
2. A Goate, MC Chartier-Harlin, M Mullan, J Brown, F Crawford, L Fidani, L Giuffra, A Haynes, N Irving, L James, et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 704-706.
3. R Sherrington, EI Rogaev, Y Liang, EA Rogaeva, G Levesque, M Ikeda, H Chi, C Lin, G Li, K Holman, T Tsuda, L Mar, JF Foncin, AC Bruni, MP Montesi, S Sorbi, I Rainero, L Pinessi, L Nee, I Chumakov, D Pollen, A Brookes, P Sanseau, RJ Polinsky, W Wasco, S.H.A.R. Da Silva HAR, JL Haines, MA Pericak-Vance, RE Tanzi, AD Roses, PE Fraser, JM Rommens and G.-H.P.H. St George-Hyslop PH (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 754-760.
4. EI Rogaev, R Sherrington, EA Rogaeva, G Levesque, M Ikeda, Y Liang, H Chi, C Lin, K Holman, T Tsuda, L Mar, S Sorbi, B Nacmias, S Piacentini, L Amaducci, I Chumakov, D Cohen, L Lannfelt, PE Fraser, JM Rommens and G.-H.P.H. St George-Hyslop PH (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376 775-778.
5. E Levy-Lahad, W Wasco, P Poorkaj, DM Romano, J Oshima, WH Pettingell, CE Yu, PD Jondro, SD Schmidt, K Wang, AC Crowley, YH Fu, SY Guenette, D Galas, E Nemens, EM Wijsman, TD Bird, GD Schellenberg and RE Tanzi (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 973-977.
6. M Hutton, CL Lendon, P Rizzu, M Baker, S Froelich, H Houlden, S Pickering-Brown, S Chakraverty, A Isaacs, A Grover, J Hackett, J Adamson, S Lincoln, D Dickson, P Davies, RC Petersen, M Stevens, G.E. de Graaff E, E Wauters, B.J. van Baren J, M Hillebrand, M Joosse, JM Kwon, P Nowotny, LK Che, J Norton, JC Morris, LA Reed, J Trojanowski, H Basun, L Lannfelt, M Neystat, S Fahn, F Dark, T Tannenberg, PR Dodd, N Hayward, JB Kwok, PR Schofield, A Andreadis, J Snowden, D Craufurd, D Neary, F Owen, BA Oostra, J Hardy, A Goate, S.J. van Swieten J, D Mann, T Lynch and P Heutink (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393 702-705.
7. S.R.H.A. De Silva RHA, NL Khan and NW Wood (2000) The genetics of Parkinson's disease. Curr Opin Genet Dev. 10 292-298.
8. MH Polymeropoulos, C Lavedan, E Leroy, SE Ide, A Dehejia, A Dutra, B Pike, H Root, J Rubenstein, R Boyer, ED Stenroos, S Chandrasekharappa, A Athanassiadou, T Papapetropoulos, WG Johnson, AM Lazzarini, RC Duvoisin, GD Iorio, LI Golbe and RL Nussbaum (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 2045-2047.
9. R Kruger, W Kuhn, T Muller, D Woitalla, M Graeber, S Kosel, H Przuntek, JT Epplen, L Schols and O Riess (1998) Ala30 → Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 18 106-108.
10. AB Singleton, M Farrer, J Johnson, A Singleton, S Hague, J Kachergus, M Hulihan, T Peuralinna, A Dutra, R Nussbaum, S Lincoln, A Crawley, M Hanson, D Maraganore, C Adler, MR Cookson, M Muenter, M Baptista, D Miller, J Blancato, J Hardy and K Gwinn-Hardy (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science 302 841.
11. E Leroy, R Boyer, G Auburger, B Leube, G Ulm, E Mezey, G Harta, MJ Brownstein, S Jonnalagada, T Chernova, A Dehejia, C Lavedan, T Gasser, PJ Steinbach, KD Wilkinson and MH Polymeropoulous (1998) The ubiquitin pathway in Parkinson's disease. Nature 395 451-452.
12. T Kitada, S Asakawa, N Hattori, H Matsumine, Y Yamamura, S Minoshima, M Yokochi, Y Mizuno and N Shimizu (1998) Mutations in the Parkin gene cause autosomal recessive juvenile Parkinsonism. Nature 392 605-608.
13. EM Valente, PM Abou-Sleiman, V Caputo, MM Muqit, K Harvey, S Gispert, Z Ali, T.D. Del Turco D, AR Bentivoglio, DG Healy, A Albanese, R Nussbaum, R Gonzalez-Maldonado, T Deller, S Salvi, P Cortelli, WP Gilks, DS Latchman, RJ Harvey, B Dallapiccola, G Auburger and NW Wood (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 1158-1160.
14. D.C.M. van Duijn CM, MC Dekker, V Bonifati, RJ Galjaard, JJ Houwing-Duistermaat, PJ Snijders, L Testers, GJ Breedveld, M Horstink, LA Sandkuijl, S.J.C. van Swieten JC, BA Oostra and P Heutink (2001) Park7, A novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet. 69 629-634.
15. WD Le, P Xu, J Jankovic, H Jiang, SH Appel, RG Smith and DK Vassilatis (2003) Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 33 85-89.
16. D Curti, A Malaspina, G Facchetti, C Camana, L Mazzini, P Tosca, F Zerbi and M Ceroni (1996) Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Neurology 47 1060-1064.
17. DR Rosen, T Siddique, D Patterson, DA Figlewicz, P Sapp, A Hentati, D Donaldson, J Goto, JP O'Regan, HX Deng, Z Rahmani, A Krizus, D McKenna-Yasek, A Cayabyab, SM Gaston, R Berger, RE Tanzi, JJ Halperin, B Herzfeldt, R Van den Bergh, W Hung, T Bird, G Deng, DW Mulder, C Smyth, NG Laing, E Soriano, MA Pericak-Vance, J Haines, GA Rouleau, JS Gusella, HR Horvitz and RH Brown Jr. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 59-62.
18. D Majoor-Krakauer, PJ Willems and A Hofman (2003) Genetic epidemiology of amyotrophic lateral sclerosis. Clin Genet. 63 83-101.
19. S Hadano, CK Hand, H Osuga, Y Yanagisawa, A Otomo, RS Devon, N Miyamoto, J Showguchi-Miyata, Y Okada, R Singaraja, DA Figlewicz, T Kwiatkowski, BA Hosler, T Sagie, J Skaug, J Nasir, RH Brown Jr., SW Scherer, GA Rouleau, MR Hayden and JE Ikeda (2001) A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet. 29 166-173.
20. Y Yang, A Hentati, HX Deng, O Dabbagh, T Sasaki, M Hirano, WY Hung, K Ouahchi, J Yan, AC Azim, N Cole, G Gascon, A Yagmour, M Ben-Hamida, M Pericak-Vance, F Hentati and T Siddique (2001) The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet. 29 160-165.
21. BO Evert, U Wullner and T Klockgether (2000) Cell death in polyglutamine diseases. Cell Tissue Res. 301 189-204.
22. JF Gusella, NS Wexler, PM Conneally, SL Naylor, MA Anderson, RE Tanzi, PC Watkins, K Ottina, MR Wallace, AY Sakaguchi, AB Young, I Shoulson, E Bonilla and JB Martin (1983) A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306 234-238.
23. V Campuzano, L Montermini, MD Molto, L Pianese, M Cossee, F Cavalcanti, E Monros, F Rodius, F Duclos, A Monticelli, F Zara, J Canizares, H Koutnikova, SI Bidichandani, C Gellera, A Brice, P Trouillas, M.G. De Michele G, A Filla, F.R. De Frutos R, F Palau, PI Patel, D.S. Di Donato S, JL Mandel, S Cocozza, M Koenig and M Pandolfo (1996) Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271 1423-1427.
24. P Gambetti, P Parchi and SG Chen (2003) Hereditary Creutzfeldt-Jakob disease and fatal familial insomnia. Clin Lab Med. 23 43-64.
25. CM Tanner, R Ottman, SM Goldman, J Ellenberg, P Chan, R Mayeux and JW Langston (1999) Parkinson disease in twins: an etiologic study. JAMA 281 341-346.
26. JW Langston, LS Forno, J Tetrud, AG Reeves, JA Kaplan and D Karluk (1999) Evidence of active nerve cell degener-ation in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 46 598-605.
27. AL McCormack, M Thiruchelvam, AB Manning-Bog, C Thiffault, JW Langston, DA Cory-Slechta and M.D.A. Di Monte DA (2002) Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis. 10 119-127.
28. B Liu, HM Gao and JS Hong (2003) Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect. 111 1065-1073.
29. RC Brown, AH Lockwood and BR Sonawane (2005) Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect. 113 1250-1256.
30. MA Hernan, B Takkouche, F Caamano-Isorna and JJ Gestal-Otero (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol. 52 276-284.
31. AI Bush (2000) Metals and neuroscience. Curr Opin Chem Biol. 4 184-191.
32. D Mergler and M Baldwin (1997) Early manifestations of manganese neurotoxicity in humans: an update. Environ Res. 73 92-100.
33. JM Gorell, CC Johnson, BA Rybicki, EL Peterson, GX Kortsha, GG Brown and RJ Richardson (1997) Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 48 650-658.
34. JM Gorell, CC Johnson, BA Rybicki, EL Peterson and RJ Richardson (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50 1346-1350.
35. KM Powers, T Smith-Weller, GM Franklin, WT Longstreth Jr., PD Swanson and H Checkoway (2003) Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 60 1761-1766.
36. JK Tsui, DB Calne, Y Wang, M Schulzer and SA Marion (1999) Occupational risk factors in Parkinson's disease. Can J Public Health 90 334-337.
37. DR McLachlan, C Bergeron, JE Smith, D Boomer and SL Rifat (1996) Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology 46 401-405.
38. CN Martyn, DN Coggon, H Inskip, RF Lacey and WF Young (1997) Aluminum concentrations in drinking water and risk of Alzheimer's disease. Epidemiology 8 281-286.
39. RA Cherny, JT Legg, CA McLean, DP Fairlie, X Huang, CS Atwood, K Beyreuther, RE Tanzi, CL Masters and AI Bush (1999) Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem. 274 23223-23228.
40. CR Cornett, WR Markesbery and WD Ehmann (1998) Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 19 339-345.
41. PM Doraiswamy and AE Finefrock (2004) Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol. 3 431-434.
42. J Mutter, J Naumann, C Sadaghiani, R Schneider and H Walach (2004) Alzheimer disease: mercury as pathogenetic factor and apolipoprotein E as a moderator. Neuro Endocrinol Lett. 25 331-339.
43. KA Jellinger (2004) Traumatic brain injury as a risk factor for Alzheimer's disease. J Neurol Neurosurg Psychiatry 75 511-512.
44. LA Shobab, GY Hsiung and HH Feldman (2005) Cholesterol in Alzheimer's disease. Lancet Neurol. 4 841-852.
45. GE Kisby, M Ellison and PS Spencer (1992) Content of the neurotoxins cycasin (methylazoxymethanol beta-D-glucoside) and BMAA (beta-N-methylamino-L-alanine) in cycad flour prepared by Guam Chamorros. Neurology 42 1336-1340.
46. V McGuire, WT Longstreth Jr., LM Nelson, TD Koepsell, H Checkoway, MS Morgan and G Van Belle (1997) Occupa-tional exposures amyotrophic lateral sclerosis. A population-based case-control study. Am J Epidemiol. 145 1076-1088.
47. AJ Hannan (2004) Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease. Acta Biochim Pol. 51 415-430.
48. S Collins, MG Law, A Fletcher, A Boyd, J Kaldor and CL Masters (1999) Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet 353 693-697.
49. L Linsell, SN Cousens, PG Smith, RS Knight, M Zeidler, G Stewart, S.R. de Silva R, TF Esmonde, HJ Ward and RG Will (2004) A case-control study of sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of clustering. Neurology 63 2077-2083.
50. JW Ironside and MW Head (2004) Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products. Haemophilia 10(Suppl. 4), 64-69.
51. W Cerpa, L Varela-Nallar, AE Reyes, AN Minniti and NC Inestrosa (2005) Is there a role for copper in neurodegenerative diseases? Mol Aspects Med. 26 405-420.
52. R Mayeux, M Sano, J Chen, T Tatemichi and Y Stern (1991) Risk of dementia in first-degree relatives of patients with Alzheimer's disease and related disorders. Arch Neurol. 48 269-273.
53. NL Pedersen, M Gatz, S Berg and B Johansson (2004) How heritable is Alzheimer's disease late in life? Findings from Swedish twins. Ann Neurol. 55 180-185.
54. LA Farrer, LA Cupples, JL Haines, B Hyman, WA Kukull, R Mayeux, RH Myers, MA Pericak-Vance, N Risch and CM Van Duijn (1997) Effects of age sex ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Anal. JAMA 278 1349-1356.
55. AJ Brookes and JA Prince (2005) Genetic association analysis: lessons from the study of Alzheimers disease. Mutat Res. 573 152-159.
56. D.E. Warwick Daw E, H Payami, EJ Nemens, D Nochlin, TD Bird, GD Schellenberg and EM Wijsman (2000) The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet. 66 196-204.
57. MI Kamboh (2004) Molecular genetics of late-onset Alzheimer's disease. Ann Hum Genet. 68 381-404.
58. X Huang, PC Chen and C Poole (2004) APOE-[varepsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 62 2198-2202.
59. P Verpillat, A Camuzat, D Hannequin, C Thomas-Anterion, M Puel, S Belliard, B Dubois, M Didic, L Lacomblez, O Moreaud, V Golfier, D Campion, A Brice and F Clerget-Darpoux (2002) Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis. Eur J Hum Genet. 10 399-405.
60. L Bertram and RE Tanzi (2005) The genetic epidemiology of neurodegenerative disease. J Clin Invest. 115 1449-1457.
61. Y Wakutani, H Kowa, M Kusumi, K Nakaso, K Yasui, K Isoe-Wada, H Yano, K Urakami, T Takeshima and K Nakashima (2004) A haplotype of the methylenetetrahydrofolate reductase gene is protective against late-onset Alzheimer's disease. Neurobiol Aging 25 291-294.
62. LL Fernandez and RM Scheibe (2005) Is MTHFR polymorphism a risk factor for Alzheimer's disease like APOE? Arq Neuropsiquiatr. 63 1-6.
63. I Rainero, M Bo, M Ferrero, W Valfre, G Vaula and L Pinessi (2004) Association between the interleukin-1alpha gene and Alzheimer's disease: a meta-analysis. Neurobiol Aging 25 1293-1298.
64. DJ Cordato and DK Chan (2004) Genetics and Parkinson's disease. J Clin Neurosci. 11 119-123.
65. A Menegon, PG Board, AC Blackburn, GD Mellick and C.D.G. Le Couteur DG (1998) Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352 1344-1346.
66. I Zuntar, S Kalanj-Bognar, E Topic, R Petlevski, M Stefanovic and V Demarin (2004) The glutathione S-transferase polymorphisms in a control population and in Alzheimer's disease patients. Clin Chem Lab Med. 42 334-339.
67. S Bernardini, L Bellincampi, S Ballerini, G Federici, R Iori, A Trequattrini, F Ciappi, F Baldinetti, P Bossu, C Caltagirone and G Spalletta (2005) Glutathione S-transferase P1*C allelic variant increases susceptibility for late-onset Alzheimer disease: association study and relationship with apolipoprote. Clin Chem. 51 944-951.
68. AJ Whitworth, DA Theodore, JC Greene, H Benes, PD Wes and LJ Pallanck (2005) Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci USA 102 8024-8029.
69. YJ Li, SA Oliveira, P Xu, ER Martin, JE Stenger, CR Scherzer, MA Hauser, WK Scott, GW Small, MA Nance, RL Watts, JP Hubble, WC Koller, R Pahwa, MB Stern, BC Hiner, J Jankovic, CG Goetz, F Mastaglia, LT Middleton, AD Roses, AM Saunders, DE Schmechel, SR Gullans, JL Haines, JR Gilbert, JM Vance, MA Pericak-Vance, C Hulette and KA Welsh-Bohmer (2003) Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 12 3259-3267.
70. YJ Li, WK Scott, L Zhang, PI Lin, SA Oliveira, T Skelly, MP Doraiswamy, KA Welsh-Bohmer, ER Martin, JL Haines, MA Pericak-Vance and JM Vance (2005) Revealing the role of glutathione S-transferase omega in age-at-onset of Alzheimer and Parkinson diseases. Neurobiol Aging 27 1087-1093.
71. A Ozturk, PP Desai, RL Minster, ST Dekosky and MI Kamboh (2005) Three SNPs in the GSTO1, GSTO2 and PRSS11 genes on chromosome 10 are not associated with age-at-onset of Alzheimer's disease. Neurobiol Aging 26 1161-1165.
72. L Arning, P Jagiello, S Wieczorek, C Saft, J Andrich and JT Epplen (2004) Glutathione S-transferase omega 1 variation does not influence age at onset of Huntington's disease. BMC Med Genet. 5 7.
73. JA Agundez, FJ Jimenez-Jimenez, A Luengo, JA Molina, M Orti-Pareja, A Vazquez, F Ramos, J Duarte, F Coria, JM Ladero, JC Alvarez-Cermeno and J Benitez (1998) Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease. Neurology 51 1587-1592.
74. L Rocha, C Garcia, M.A. de Mendonca A, JP Gil, DT Bishop and MC Lechner (1999) N-acetyltransferase (NAT2) genotype and susceptibility of sporadic Alzheimer's disease. Pharmacogenetics 9 9-15.
75. N Johnson, P Bell, V Jonovska, M Budge and E Sim (2004.) NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant. BMC Med Genet. 5 6.
76. A Rocchi, D Micheli, R Ceravolo, ML Manca, G Tognoni, G Siciliano and L Murri (2003) Serotoninergic polymor-phisms (5-HTTLPR and 5-HT2A) : association studies with psychosis in Alzheimer disease. Genet Test. 7 309-314.
77. F Assal, M Alarcon, EC Solomon, D Masterman, DH Geschwind and JL Cummings (2004) Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. 61 1249-1253.
78. JP Julien (2001) Amyotrophic lateral sclerosis. Unfolding the toxicity of the misfolded. Cell 104 581-591.
79. ME MacDonald, JP Vonsattel, J Shrinidhi, NN Couropmitree, LA Cupples, ED Bird, JF Gusella and RH Myers (1999) Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Neurology 53 1330-1332.
80. G Perry, A Nunomura, K Hirai, X Zhu, M Perez, J Avila, RJ Castellani, CS Atwood, G Aliev, LM Sayre, A Takeda and MA Smith (2002) Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med. 33 1475-1479.
81. L Migliore, I Fontana, R Colognato, F Coppedè, G Siciliano and L Murri (2005) Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging 26 587-595.
82. E Mariani, MC Polidori, A Cherubini and P Mecocci (2005) Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B 827 65-75.
83. B Dawe, A Procter and M Philpot (1992) Concepts of mild cognitive impairment in the elderly and their relationship to dementia: a review. Int J Geriatr Psychiatry 7 473-479.
84. RC Petersen, GE Smith, S Waring, RJ Ivnik, EG Tangalos and E Kokmen (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 53 303-308.
85. L Migliore, I Fontana, F Trippi, R Colognato, F Coppedè, G Tognoni, B Nucciarone and G Siciliano (2005) Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 26 567-573.
86. TI Williams, BC Lynn, WR Markesbery and MA Lovell (2006) Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's d. Neurobiol Aging 27 1094-1099.
87. J Wang, WR Markesbery and MA Lovell (2006) Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem. 96 825-832.
88. PI Moreira, MA Smith, X Zhu, K Honda, HG Lee, G Aliev and G Perry (2005) Oxidative damage and Alzheimer's disease: are antioxidant therapies useful? Drug News Perspect. 18 13-19.
89. WR Markesbery, RJ Kryscio, MA Lovell and JD Morrow (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol. 58 730-735.
90. MA Lovell, WD Ehmann, MP Mattson and WR Markesbery (1997) Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18 457-461.
91. LT McGrath, BM McGleenon, S Brennan, D McColl, S McILroy and AP Passmore (2001) Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 94 485-490.
92. ML Selley, DR Close and SE Stern (2002) The effect of increased concentrations of homocysteine on the concentration of (E) -4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with. Neurobiol Aging 23 383-388.
93. TJ Montine, MF Beal, ME Cudkowicz, H O'Donnell, RA Margolin, L McFarland, AF Bachrach, WE Zackert, LJ Roberts and JD Morrow (1999) Increased CSF F2-isoprostane concentration in probable AD. Neurology 52 562-565.
94. E Waddington, K Croft, R Clarnette and R Artins (1999) Plasma F2-isoprostane levels are increased in Alzheimer's disease: evidence of increased oxidative stress in vivo. Alzheimers' Rep. 2 227-282.
95. EE Tuppo, LJ Forman, BW Spur, RE Cheng-Ting, A Chopra and A Cavalieri (2001) Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res Bull. 54 565-568.
96. D Praticò, C Clark, VM Lee, JQ Trojanowski, J Rokach and GA Fitzgerald (2000) Increased 8, 12-iso-iPF (2 alpha) -IV in Alzheimer's disease: correlation of specific noninvasive index of lipid peroxidation with disease severity. Ann Neurol. 48 809-812.
97. C Cecchi, C Fiorillo, S Sorbi, S Latorraca, B Nacmias, S Bagnoli, P Nassi and G Liguri (2002) Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med. 33 1372-1379.
98. J Choi, CA Malakowsky, JM Talent, CC Conrad and RW Gracy (2002) Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun. 293 1566-1570.
99. CC Conrad, PL Marshall, JM Talent, CA Malakowsky, J Choi and RW Gracy (2000) Oxidized proteins in Alzheimer's plasma. Biochem Biophys Res Commun. 275 678-681.
100. P Mecocci, C Polidori, A Cherubini, F Chionne, R Cecchetti and U Senin (1998) Oxidative damage to DNA lympocytes from AD patients. Neurology 51 1014-1017.
101. P Mecocci, MC Polidori, A Cherubini, T Ingegni, P Mattioli, M Catani, P Rinaldi, R Cecchetti, W Stahl, U Senin and MF Beal (2002) Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol. 59 794-798.
102. E Kadioglu, S Sardas, S Aslan, E Isik and K.A. Esat Karakaya A (2004) Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer's disease. Biomarkers 9 203-209.
103. M Mòrocz, J Kalman, A Juhàsz, I Sinkò, AP McGlynn, CS Downes, Z Janka and I Raskò (2002) Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. Neurobiol Aging 23 47-53.
104. P Rinaldi, MC Polidori, A Metastasio, E Mariani, P Mattioli, A Cherubini, M Catani, R Cecchetti, U Senin and P Mecocci (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24 915-919.
105. TV Ilic, M Jovanovic, A Jovicic and M Tomovic (1999) Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct Neurol. 14 141-147.
106. J Kalra, AH Rajput, SV Mantha, AK Chaudhary and K Prasad (1992) Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease. Mol Cell Biochem. 112 181-186.
107. JA Serra, RO Dominguez, L.E.S. de Lustig ES, EM Guareschi, AL Famulari, EL Bartolome and ER Marschoff (2001) Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementi. J Neural Transm. 108 1135-1148.
108. C Buhmann, S Arlt, A Kontush, T Moller-Bertram, S Sperber, M Oechsner, HJ Stuerenburg and U Beisiegel (2004) Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication. Neurobiol Dis. 15 160-170.
109. F Blandini, E Martignoni, R Ricotti, J.F. di Jeso F and G Nappi (2005) Determination of hydroxyl free radical forma-tion in human platelets using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl. 732 213-220.
110. A Kikuchi, A Takeda, H Onodera, T Kimpara, K Hisanaga, N Sato, A Nunomura, RJ Castellani, G Perry, MA Smith and Y Itoyama (2002) Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis. 9 244-248.
111. L Migliore, L Petrozzi, C Lucetti, G Gambaccini, S Bernardini, R Scarpato, F Trippi, R Barale, G Frenzilli, V Rodilla and U Bonuccelli (2002) Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58 1809-1815.
112. H Tohgi, T Abe, K Yamazaki, T Murata, E Ishizaki and C Isobe (1999) Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 46 129-131.
113. RG Smith, YK Henry, MP Mattson and SH Appel (1998) Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 44 696-699.
114. EP Simpson, YK Henry, JS Henkel, RG Smith and SH Appel (2004) Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 62 1758-1765.
115. M Bogdanov, RH Brown, W Matson, R Smart, D Hayden, H O'Donnell, B.M. Flint Beal M and M Cudkowicz (2000) Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med. 29 652-658.
116. Y Ihara, A Mori, T Hayabara, M Kawai, R Namba, K Nobukuni, K Sato and M Kibata (1995) Superoxide dismutase and free radicals in sporadic amyotrophic lateral sclerosis: relationship to clinical data. J Neurol Sci. 134 51-56.
117. S Apostolski, Z Marinkovic, A Nikolic, D Blagojevic, MB Spasic and AM Michelson (1998) Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation. J Environ Pathol Toxicol Oncol. 17 325-329.
118. D Bonnefont-Rousselot, L Lacomblez, M Jaudon, S Lepage, F Salachas, G Bensimon, C Bizard, V Doppler, J Delattre and V Meininger (2000) Blood oxidative stress in amyotrophic lateral sclerosis. J Neurol Sci. 178 57-62.
119. PI Oteiza, OD Uchitel, F Carrasquedo, AL Dubrovski, JC Roma and CG Fraga (1997) Evaluation of antioxidants, pro-tein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem Res. 22 535-539.
120. E Bossy-Wetzel, R Schwarzenbacher and SA Lipton (2004) Molecular pathways to neurodegeneration. Nat Med. 10 S2-S9. Suppl.
121. DA Butterfield (2004) Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res. 1000 1-7.
122. J Zhang and DR Goodlett (2004) Proteomic approach to studying Parkinson's disease. Mol Neurobiol. 29 271-288.
123. K Honda, MA Smith, X Zhu, D Baus, WC Merrick, AM Tartakoff, T Hattier, PL Harris, SL Siedlak, H Fujioka, Q Liu, PI Moreira, FP Miller, A Nunomura, S Shimohama and G Perry (2005) Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem. 280 20978-20986.
124. Q Ding, WR Markesbery, Q Chen, F Li and JN Keller (2005) Ribosome dysfunction is an early event in Alzheimer's disease. J Neurosci. 25 9171-9175.
125. A Campbell (2002) The potential role of aluminium in Alzheimer's disease. Nephrol Dial Transplant. 2 17-20.
126. P Fattoretti, C Bertoni-Freddari, M Balietti, E Mocchegiani, J Scancar, P Zambenedetti and P Zatta (2003) The effect of chronic aluminium (III) administration on the nervous system of aged rats: clues to understand its suggested role in Alzheimer's disease. J Alzheimers Dis. 5 437-444.
127. A Khan, JP Dobson and C Exley (2006) Redox cycling of iron by Abeta (42). Free Radic Biol Med. 40 557-569.
128. MA Lovell, JL Smith, S Xiong and WR Markesbery (2005) Alterations in zinc transporter protein-1 (ZnT-1) in the brain of subjects with mild cognitive impairment, early, and late-stage Alzheimer's disease. Neurotox Res. 7 265-271.
129. JL Smith, S Xiong and MA Lovell (2006) 4-Hydroxynonenal disrupts zinc export in primary rat cortical cells. Neurotoxicology in press
130. K Schuessel, S Schafer, TA Bayer, C Czech, L Pradier, F Muller-Spahn, WE Muller and A Eckert (2005) Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol Dis. 18 89-99.
131. KS Kim, SY Choi, HY Kwon, MH Won, TC Kang and JH Kang (2002) Aggregation of alpha-synuclein induced by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. Free Radic Biol Med. 32 544-550.
132. X Zhu, AK Raina, HG Lee, M Chao, A Nunomura, M Tabaton, RB Petersen, G Perry and MA Smith (2003) Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways. Antioxid Redox Signal. 5 571-576.
133. G Aliev, MA Smith, T.J.C. de la Torre JC and G Perry (2004) Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion 4 649-663.
134. KG Manton, S Volovik and A Kulminski (2004) ROS effects on neurodegeneration in Alzheimer's disease and related disorders: on environmental stresses of ionizing radiation. Curr Alzheimer Res. 1 277-293.
135. PI Moreira, K Honda, Q Liu, MS Santos, CR Oliveira, G Aliev, A Nunomura, X Zhu, MA Smith and G Perry (2005) Oxidative stress: the old enemy in Alzheimer's disease pathophysiology. Curr Alzheimer Res. 2 403-408.
136. X Zhu, MA Smith, G Perry and G Aliev (2004) Mitochondrial failures in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 19 345-352.
137. MO Hengartner (2000) The biochemistry of apoptosis. Nature 407 770-776.
138. T Dragovich, CM Rudin and CB Thompson (1998) Signal transduction pathways that regulate cell survival and cell death. Oncogene 17 3207-3213.
139. S Krantic, N Mechawar, S Reix and R Quirion (2005) Molecular basis of programmed cell death involved in neurodegeneration. Trends Neurosci. 28(12), 670-676.
140. M Pollack and C Leeuwenburgh (2001) Apoptosis and aging: role of the mitochondria. J Gerontol A Biol Sci Med Sci. 56(11), B475-B482.
141. Y Higami and I Shimokawa (2000) Apoptosis in the aging process. Cell Tissue Res. 301 125-132.
142. M Zhao, J Su, E Head and CW Cotman (2003) Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer's disease. Neurobiol Dis. 14(3), 391-403.
143. CW Cotman, WW Poon, RA Rissman and M Blurton-Jones (2005) The role of caspase cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp Neurol. 64 104-112.
144. M.S.M. De la Monte SM, YK Sohn and JR Wands (1997) Correlates of p53-and Fas (CD95) -mediated apoptosis in Alzheimer's disease. J Neurol Sci. 152(1), 73-83.
145. Y Ohyagi, H Asahara, DH Chui, Y Tsuruta, N Sakae, K Miyoshi, T Yamada, H Kikuchi, T Taniwaki, H Murai, K Ikezoe, H Furuya, T Kawarabayashi, M Shoji, F Checler, T Iwaki, T Makifuchi, K Takeda, J Kira and T Tabira (2005) Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J. 19(2), 255-257.
146. MM Tompkins, EJ Basgall, E Zamrini and WD Hill (1997) Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol. 150(1), 119-131.
147. MH Polymeropoulos (1998) Autosomal dominant Parkinson's disease and alpha-synuclein. Ann Neurol. 44 S63-S64.
148. M Yamada, T Iwatsubo, Y Mizuno and H Mochizuki (2004) Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspas. J Neurochem. 91 451-461.
149. S Przedborski (2004) Programmed cell death in amyotrophic lateral sclerosis: a mechanism of pathogenic and therapeutic importance. Neurologist 10(1), 1-7.
150. MF Perutz, T Johnson, M Suzuki and JT Finch (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 91(12), 5355-5358.
151. SH Li, S Lam, AL Cheng and XJ Li (2000) Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. Hum Mol Genet. 9(19), 2859-2867.
152. M Kristiansen, MJ Messenger, PC Klohn, S Brandner, JD Wadsworth, J Collinge and SJ Tabrizi (2005) Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis. J Biol Chem. 280(46), 38851-38861.
153. AC Rego and CR Oliveira (2003) Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem Res. 28(10), 1563-1574.
154. K Komjati, JG Mabley, L Virag, GJ Southan, AL Salzman and C Szabo (2004) Poly (ADP-ribose) polymerase inhi-bition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. Int J Mol Med. 13 373-382.
155. H Wang, SW Yu, DW Koh, J Lew, C Coombs, W Bowers, HJ Federoff, GG Poirier, TM Dawson and VL Dawson (2004) Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J Neurosci. 24(48), 10963-10973.
156. Z Nagy, MM Esiri and AD Smith (1998) The cell division cycle and the pathophysiology of Alzheimer's disease. Neuroscience 87(4), 731-739.
157. Y Yang, EJ Mufson and K Herrup (2003) Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci. 23(7), 2557-2563.
158. II Kruman, RP Wersto, F Cardozo-Pelaez, L Smilenov, SL Chan, FJ Chrest, R Emokpae Jr., M Gorospe and MP Mattson (2004) Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 41(4), 549-561.
159. T Perls (2004) Dementia-free centenarians. Exp Gerontol. 39 1587-1593.
160. R Hitt, Y Young-Xu, M Silver and T Perls (1999) Centenarians: the older you get, the healthier you have been. Lancet 354 652.
161. RG Cutler (1975) Evolution of human longevity and the genetic complexity governing aging rate. Proc Natl Acad Sci USA 72 4664-4668.
162. L Migliore and F Coppedè (2002) Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat Res. 512 135-153.
163. DM Walsh and DJ Selkoe (2004) Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 11 213-228.